Tonix Pharmaceuticals: reports Q3 2026 TONMYA revenue $14,000,000 to $15,000,000

What happened

• Tonix Pharmaceuticals filed an 8-K disclosing selected preliminary operating results for the 3 months ended Sep 30, 2026. The Company reported that net revenue for TONMYA is estimated to be between $14,000,000 and $15,000,000 for the quarter and that cash and cash equivalents were approximately $162,800,000 as of Sep 30, 2026.
• The filing says the unaudited, estimated results are preliminary, were prepared by management based on estimates and currently available information, and are subject to completion and revision.

Key details

• TONMYA net revenue for the 3 months ended Sep 30, 2026 is estimated between $14,000,000 and $15,000,000.
• Cash and cash equivalents were estimated at approximately $162,800,000 as of Sep 30, 2026.
• The Company describes these results as preliminary and unaudited and notes they may be materially different after quarter-end closing procedures and completion of consolidated financial statements.
• The 8-K includes Item 2.02 (results of operations). The filing text also references Item 8.01 (other events).

Why it may matter

• Item 2.02 (results of operations and financial condition) covers preliminary operating results and the Company’s estimated financial position for the reported quarter. The filing states the preliminary information was prepared in good faith by management but may be revised during financial close procedures. This filing does not show why an insider traded or why the company acted.